Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir

Introduction: Viral hepatitis B is a major public health problem worldwide. The aim of this study was to evaluate the clinico-biological parameters in patients with chronic on Tenofovir. Patients and method: This cross-sectional retrospective data collection from April 1, 2019 March 31, 2021, i.e. two years. aged at least 15 years, regardless sex, complete follow-up file were included. Results: A total 920 files evaluated, which 145 met inclusion criteria, frequency 15.76%. male predominance found (sex ratio 2.62). average age 33.24 years extremes 17 63 Students more represented (36.6%). Incidental discovery most frequent mode (29.7%). Asthenia clinical manifestation (28.27%). Cytolysis 82.76% cases start treatment. Creatinine levels normal cases. HBV DNA > 2000 IU/ml 92.41% Abdominal ultrasound 51.25% Biological fibrosis scores (APRI FIB-4) used almost one third patients. evolution marked by virological response 82.35% 12th month normalization transaminases 91.6% Conclusion: B, problem, among young people our context. Tenofovir, effective, allows obtain significant transaminases.